Table 2.
Patient-level characteristics
| Number of patients (N = 73)* | ||
|---|---|---|
| Age at diagnosis of advanced/metastatic solid cancer, years (median, IQR) | 61 | 55–68 |
| Sex assigned at birth (male n, %) | 38 | 52.1% |
| Solid tumor type (n, %) | ||
| Lung | 20 | 27.4% |
| Thyroid | 13 | 17.8% |
| Salivary gland | 10 | 13.7% |
| Colorectal | 9 | 12.3% |
| Other soft tissue sarcomas | 7 | 9.6% |
| Cholangiocarcinoma | 6 | 8.2% |
| Breast | 5 | 6.8% |
| Pancreatic | 3 | 4.1% |
| Tests or panel types for determining patient's NTRK gene fusion status (n, %) | ||
| Next generation sequencing (NGS) | 61 | 83.6% |
| Fluorescent in situ hybridization studies (FISH) | 11 | 15.1% |
| Full panel or select panel | 1 | 1.4% |
| Timing of NTRK tests/panels for determining patients’ NTRK gene fusion status (n, %)1 | ||
| Baseline (around diagnosis)/prior to 1L initiation | 31 | 42.5% |
| During 1L therapy | 6 | 8.2% |
| Immediately after 1L therapy | 9 | 12.3% |
| Prior to initiation 2L+ therapy | 15 | 20.5% |
| At time of recurrence | 6 | 8.2% |
| At time of metastatic diagnosis | 8 | 11.0% |
| After 2L therapy | 2 | 2.7% |
| Treatment/therapy immediately following NTRK+ gene fusion test (n, %) | ||
| Larotrectinib | 41 | 56.2% |
| Entrectinib | 18 | 24.7% |
| Pemetrexed | 2 | 2.7% |
| Chemo-immunotherapy | 2 | 2.7% |
| FOLFOX plus bevacizumab | 2 | 2.8% |
| Alectinib | 1 | 1.4% |
| Carboplatin/pemetrexed/pembrolizumab | 1 | 1.4% |
| Cisplatin/gemcitabine | 1 | 1.4% |
| FOLFOX | 1 | 1.4% |
| Pembrolizumab | 1 | 1.4% |
| Pembrolizumab plus chemotherapy | 1 | 1.4% |
| Trabectedin | 1 | 1.4% |
| Chemotherapy (not specified) | 1 | 1.4% |
| Patient status at time of chart abstraction (n, %) | ||
| Alive, on current treatment | 49 | 67.1% |
| Alive, but needs new treatment | 2 | 2.7% |
| Alive, receiving palliative care only | 1 | 1.4% |
| Deceased | 21 | 28.8% |
1L first-line, 2L second-line, IQR interquartile range, NGS next-generation sequencing; NTRK+ neurotrophic tropomyosin-related kinase gene fusion-positive, SD standard deviation
*Physicians (N = 28) submitted patient-level data for up to 3 NTRK+ patients meeting study inclusion criteria
aNot mutually exclusive